Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO(TM)

Stock Information for Cidara Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cidara Therapeutics Inc.

Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development
Cidara Therapeutics to Participate in The Citizens Life Sciences Conference
Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response
Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.